156 related articles for article (PubMed ID: 31841301)
1. An Immune-Stimulatory Helix-Loop-Helix Peptide: Selective Inhibition of CTLA-4-B7 Interaction.
Ramanayake Mudiyanselage TMR; Michigami M; Ye Z; Uyeda A; Inoue N; Sugiura K; Fujii I; Fujiwara D
ACS Chem Biol; 2020 Feb; 15(2):360-368. PubMed ID: 31841301
[TBL] [Abstract][Full Text] [Related]
2. Generation of molecular-targeting helix-loop-helix peptides for inhibition of the interaction between cytotoxic T-lymphocyte-associated protein 4 and B7 in the dog.
Ramanayake Mudiyanselage TM; Fujiwara D; Michigami M; Watanabe S; Ye Z; Ueda A; Kanegi R; Hatoya S; Fujii I; Sugiura K
J Vet Med Sci; 2022 Aug; 84(8):1101-1107. PubMed ID: 35753760
[TBL] [Abstract][Full Text] [Related]
3. Chimeric co-stimulatory molecules that selectively act through CD28 or CTLA-4 on human T cells.
Lazetic S; Leong SR; Chang JC; Ong R; Dawes G; Punnonen J
J Biol Chem; 2002 Oct; 277(41):38660-8. PubMed ID: 12167647
[TBL] [Abstract][Full Text] [Related]
4. Peptide Blocking CTLA-4 and B7-1 Interaction.
Podlesnykh SV; Abramova KE; Gordeeva A; Khlebnikov AI; Chapoval AI
Molecules; 2021 Jan; 26(2):. PubMed ID: 33419027
[TBL] [Abstract][Full Text] [Related]
5. Selective blockade of CD28 and not CTLA-4 with a single-chain Fv-alpha1-antitrypsin fusion antibody.
Vanhove B; Laflamme G; Coulon F; Mougin M; Vusio P; Haspot F; Tiollier J; Soulillou JP
Blood; 2003 Jul; 102(2):564-70. PubMed ID: 12649149
[TBL] [Abstract][Full Text] [Related]
6. B7-CD28 interaction is a late acting co-stimulatory signal for human T cell responses.
Zhang YQ; Joost van Neerven RJ; Van Gool SW; Coorevits L; de Boer M; Ceuppens JL
Int Immunol; 1997 Aug; 9(8):1095-102. PubMed ID: 9263006
[TBL] [Abstract][Full Text] [Related]
7. Revealing the atomistic details behind the binding of B7-1 to CD28 and CTLA-4: A comprehensive protein-protein modelling study.
Ganesan A; Moon TC; Barakat KH
Biochim Biophys Acta Gen Subj; 2018 Dec; 1862(12):2764-2778. PubMed ID: 30251665
[TBL] [Abstract][Full Text] [Related]
8. Targeting B7-1 in immunotherapy.
Chen R; Ganesan A; Okoye I; Arutyunova E; Elahi S; Lemieux MJ; Barakat K
Med Res Rev; 2020 Mar; 40(2):654-682. PubMed ID: 31448437
[TBL] [Abstract][Full Text] [Related]
9. Porcine CTLA4-Ig lacks a MYPPPY motif, binds inefficiently to human B7 and specifically suppresses human CD4+ T cell responses costimulated by pig but not human B7.
Vaughan AN; Malde P; Rogers NJ; Jackson IM; Lechler RI; Dorling A
J Immunol; 2000 Sep; 165(6):3175-81. PubMed ID: 10975832
[TBL] [Abstract][Full Text] [Related]
10. The IgV domain of human B7-2 (CD86) is sufficient to co-stimulate T lymphocytes and induce cytokine secretion.
Rennert P; Furlong K; Jellis C; Greenfield E; Freeman GJ; Ueda Y; Levine B; June CH; Gray GS
Int Immunol; 1997 Jun; 9(6):805-13. PubMed ID: 9199963
[TBL] [Abstract][Full Text] [Related]
11. Activated human B lymphocytes express three CTLA-4 counterreceptors that costimulate T-cell activation.
Boussiotis VA; Freeman GJ; Gribben JG; Daley J; Gray G; Nadler LM
Proc Natl Acad Sci U S A; 1993 Dec; 90(23):11059-63. PubMed ID: 7504293
[TBL] [Abstract][Full Text] [Related]
12. Molecular and Cellular Functions of CTLA-4.
Van Coillie S; Wiernicki B; Xu J
Adv Exp Med Biol; 2020; 1248():7-32. PubMed ID: 32185705
[TBL] [Abstract][Full Text] [Related]
13. CTLA-4 is a second receptor for the B cell activation antigen B7.
Linsley PS; Brady W; Urnes M; Grosmaire LS; Damle NK; Ledbetter JA
J Exp Med; 1991 Sep; 174(3):561-9. PubMed ID: 1714933
[TBL] [Abstract][Full Text] [Related]
14. Targeting T cell costimulation in autoimmune disease.
Stuart RW; Racke MK
Expert Opin Ther Targets; 2002 Jun; 6(3):275-89. PubMed ID: 12223069
[TBL] [Abstract][Full Text] [Related]
15. Immune inhibitory function of bovine CTLA-4 and the effects of its blockade in IFN-γ production.
Watari K; Konnai S; Maekawa N; Okagawa T; Suzuki Y; Murata S; Ohashi K
BMC Vet Res; 2019 Oct; 15(1):380. PubMed ID: 31665022
[TBL] [Abstract][Full Text] [Related]
16. Activation of human peripheral blood dendritic cells induces the CD86 co-stimulatory molecule.
McLellan AD; Starling GC; Williams LA; Hock BD; Hart DN
Eur J Immunol; 1995 Jul; 25(7):2064-8. PubMed ID: 7542604
[TBL] [Abstract][Full Text] [Related]
17. Generation and evaluation of the efficacy of rhesus monkey soluble cytotoxic T lymphocyte-associated antigen-4 in the allogeneic mixed lymphocyte reaction.
Kim JS; Choi I; Lee HH; Lee SJ; Na M; Kim SH; Han J; Bae J; Choi SP; Kim SJ; Park CG; Chun T
Biotechnol Lett; 2012 Dec; 34(12):2191-7. PubMed ID: 22936302
[TBL] [Abstract][Full Text] [Related]
18. Immunoinhibitory DNA vaccine protects against autoimmune diabetes through cDNA encoding a selective CTLA-4 (CD152) ligand.
Prud'homme GJ; Chang Y; Li X
Hum Gene Ther; 2002 Feb; 13(3):395-406. PubMed ID: 11860706
[TBL] [Abstract][Full Text] [Related]
19. A DNA vaccine against cytotoxic T-lymphocyte associated antigen-4 (CTLA-4) prevents tumor growth.
Lan KH; Liu YC; Shih YS; Tsaid CL; Yen SH; Lan KL
Biochem Biophys Res Commun; 2013 Oct; 440(2):222-8. PubMed ID: 24041689
[TBL] [Abstract][Full Text] [Related]
20. Expression and functional significance of an additional ligand for CTLA-4.
Lenschow DJ; Su GH; Zuckerman LA; Nabavi N; Jellis CL; Gray GS; Miller J; Bluestone JA
Proc Natl Acad Sci U S A; 1993 Dec; 90(23):11054-8. PubMed ID: 7504292
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
